Real-life use of liraglutide 3 mg in obesity management: The SAX-RL study

Diabetes Obes Metab. 2024 Nov;26(11):5488-5491. doi: 10.1111/dom.15845. Epub 2024 Aug 21.

Authors

Marc Goëau-Brissonnière¹, Claire Rives-Lange^{1

2

3}, Aurélie Phan^{1

3}, Eleni Kourti^{1

3}, Nathalie Rassy¹, Estelle Lu⁴, Charles Barsamian¹, Sébastien Czernichow^{1

2

3}, Claire Carette^{1

3

5}

Affiliations

¹ Service de Nutrition, Centre Spécialisé Obésité, AP-HP, Hôpital Européen Georges-Pompidou, Paris, France.
² INSERM, CRESS, UMR1153, Paris, France.
³ Université Paris Cité, Paris, France.
⁴ Informatique Médicale, AP-HP, Hôpital Européen Georges-Pompidou, Paris, France.
⁵ CIC1418 and DMU CARTE, AP-HP, Hôpital Européen Georges-Pompidou, Paris, France.

PMID: 39169527
DOI: 10.1111/dom.15845

No abstract available

Keywords: antidiabetic drug; antiobesity drug; obesity therapy; weight management; GLP‐1 receptor agonist.

Publication types

Letter
Multicenter Study

MeSH terms

Adult
Diabetes Mellitus, Type 2 / drug therapy
Female
Humans
Hypoglycemic Agents* / therapeutic use
Liraglutide* / therapeutic use
Male
Middle Aged
Obesity Management / methods
Obesity* / drug therapy
Treatment Outcome

Substances

Liraglutide
Hypoglycemic Agents